Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial

Maznyczka, A. M. et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107(4), pp. 299-312. (doi: 10.1136/heartjnl-2020-317828) (PMID:33436493)

[img] Text
226108.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

2MB

Abstract

Objectives: Persistently impaired culprit artery flow (<TIMI 3) during primary percutaneous coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects of intracoronary alteplase according to TIMI flow grade immediately preceding drug administration. Methods: In T-TIME (trial of low-dose adjunctive alTeplase during primary PCI), patients ≤6 hours from onset of ST-elevation myocardial infarction (STEMI) were randomised to placebo, alteplase 10 mg or alteplase 20 mg, administered by infusion into the culprit artery, pre-stenting. In this prespecified, secondary analysis, coronary flow was assessed angiographically at the point immediately before drug administration. Microvascular obstruction, myocardial haemorrhage and infarct size were assessed by cardiovascular magnetic resonance (CMR) at 2–7 days and 3 months. Results: TIMI flow was assessed after first treatment (balloon angioplasty/aspiration thrombectomy), immediately pre-drug administration, in 421 participants (mean age 61±10 years, 85% male) and was 3, 2 or 1 in 267, 134 and 19 participants respectively. In patients with TIMI flow ≤2 pre-drug, there was higher incidence of microvascular obstruction with alteplase (alteplase 20 mg (53.1%) and 10 mg (59.5%) combined versus placebo (34.1%); OR=2.47 (95% CI 1.16 to 5.22, p=0.018) interaction p=0.005) and higher incidence of myocardial haemorrhage (alteplase 20 mg (53.1%) and 10 mg (57.9%) combined vs placebo (27.5%); OR=3.26 (95% CI 1.44 to 7.36, p=0.004) interaction p=0.001). These effects were not observed in participants with TIMI 3 flow pre-drug. There were no interactions between TIMI flow pre-drug, alteplase and 3-month CMR findings. Conclusion: In patients with impaired culprit artery flow (<TIMI 3) after initial balloon angioplasty/thrombus aspiration, intracoronary alteplase was associated with increased presence of microvascular obstruction and myocardial haemorrhage.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Berry, Professor Colin and Macfarlane, Professor Peter and McConnachie, Professor Alex and McEntegart, Dr Margaret and Welsh, Dr Paul and Maznyczka, Dr Annette Marie and Petrie, Professor Mark and McCartney, Dr Peter and Eteiba, Dr Hany and Tait, Dr Robert and Duklas, Mrs Patrycja and Oldroyd, Dr Keith and Sattar, Professor Naveed and Ford, Professor Ian
Authors: Maznyczka, A. M., McCartney, P., Duklas, P., McEntegart, M., Oldroyd, K., Greenwood, J., Muir, D., Chowdhary, S., Gershlick, A. H., Eteiba, H., Cotton, J., Wragg, A., Curzen, N., Tait, R., Macfarlane, P., Welsh, P., Sattar, N., Petrie, M., Ford, I., Fox, K., McConnachie, A., and Berry, C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Heart
Publisher:BMJ Publishing Group
ISSN:1355-6037
ISSN (Online):1468-201X
Published Online:15 January 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in Heart 107(4): 299-312
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceRhian TouyzBritish Heart Foundation (BHF)RE/18/6/34217CAMS - Cardiovascular Science
174049T-TIME Coronary Physiology StudyColin BerryBritish Heart Foundation (BHF)FS/16/74/32573Institute of Cardiovascular & Medical Sciences